Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
respiratory syncytial virus vaccine (recombinant, adjuvanted) (GSK, eda7ed)
- Development stage
- Approved
- Lead developer
- GSK
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Administration
- intramuscular
01
Overview
Arexvy (respiratory syncytial virus vaccine (recombinant, adjuvanted), also known as RSVPreF3-AS01E or GSK3844766A) is an adjuvanted recombinant subunit vaccine developed by GSK for the prevention of lower respiratory tract disease (LRTD) caused by respiratory syncytial virus (RSV). It contains a recombinant RSV glycoprotein F stabilized in the prefusion conformation (RSVPreF3) combined with GSK's proprietary AS01E adjuvant system, which consists of QS-21 (a plant extract from Quillaja saponaria) and 3-O-desacyl-4'-monophosphoryl lipid A (MPL) formulated in liposomes. The vaccine is approved for active immunization in adults aged 60 years and older, as well as adults aged 18 to 59 years who are at increased risk for RSV-associated LRTD.
- Brand names
- Arexvy
- Other names
- recombinant respiratory syncytial virus pre-fusion F protein vaccineRSVPreF3 adjuvanted vaccineRSVPreF-3 adjuvanted vaccineRSVPreF 3 adjuvanted vaccineRSVPreF3-AS01ERSVPreF-3-AS01ERSVPreF 3-AS01E
02
Targets
RSV F (Respiratory syncytial virus fusion protein)
Beyond the preview
Go deeper on respiratory syncytial virus vaccine (recombinant, adjuvanted) (GSK, eda7ed).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on respiratory syncytial virus vaccine (recombinant, adjuvanted) (GSK, eda7ed).